Vol. 5 No. 4 (2025)
Reimbursement Reviews

Avapritinib (Ayvakyt)

decorative image of the issue cover

Published April 9, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses avapritinib (Ayvakyt), 25 mg, 50 mg, 100 mg, and 200 mg film-coated tablets, oral.
  • Indication: For the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.